Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Chronic Pseudomonas Aeruginosa Infection Clear all

Conditions: Cystic Fibrosis, Chronic Bronchitis
Interventions: IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 14 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more

Conditions: Cystic Fibrosis
Interventions: Arikayce™ 560 mg, Placebo for 560 mg, Arikayce™ 70 mg, Arikayce™ 140 mg, Placebo for 70 mg / 140 mg; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 16 more

Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more

Conditions: Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Interventions: BX004, Placebo; Biological · Other
Lead sponsor: BiomX Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 11 more

Conditions: Cystic Fibrosis
Interventions: AZLI, Placebo to match AZLI, Tobramycin inhalation solution; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more

Conditions: Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions: RSP-1502, Tobramycin inhalation solution; Drug
Lead sponsor: Respirion Pharmaceuticals Pty Ltd; Industry
Eligibility: 12 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin dispersion for inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more

Conditions: Bronchiectasis
Interventions: 280 mg Arikayce™, Matching Placebo for Cohort 1, 560 mg Arikayce™, Matching Placebo for Cohort 2; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions: Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 12 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 54
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions: AZLI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Up to 12 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more

Conditions: Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions: TOBI® PODHALER®, TOBI®, Bethkis®, Cayston®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 47
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Bellflower, California + 43 more

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin dispersion for inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 30
States / cities: Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more

Conditions: Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Interventions: BX004-A, Placebo; Drug
Lead sponsor: BiomX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more

Search by objective public record fields.

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Study With Phage for CF Subjects With Pseudomonas Lung Infection

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection